Head to head
Gilead Sciences vs Eli Lilly and Co
Side-by-side on the measures that matter, with a plain-English read. Full detail: GILD · LLY
GILD
Gilead Sciences
151.17+2.77%
1-year price shape — +32% over the period
Quant Rating B · 70/100
vs
LLY
Eli Lilly and Co
1,179.27+0.83%
1-year price shape — +39% over the period
Quant Rating B · 77/100
1-year performance, rebased to 100
Eli Lilly and Co edges it on the scoreable measures. Eli Lilly and Co has the highest Quant Rating (77); Eli Lilly and Co has done best over the past year (+39%); Eli Lilly and Co earns the most per share.
| GILD | LLY | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Drug Manufacturers - General |
| Last price | 151.17 | 1,179.27 |
| Change today | +2.77% | +0.83% |
| 1-year return | +31.9% | +38.7% |
| Market cap | $187.44B | $1.11T |
| 52-week range | 111.27 – 154.51 | 778.93 – 1,292.65 |
| Valuation | ||
| P/E (TTM) | -57.05 | 39.59 |
| P/E percentile, own 5-yr range | 2nd | 6th |
| P/B | 15.85 | 32.77 |
| Dividend yield | 2.13% | 0.55% |
| Profitability & growth | ||
| EPS (TTM) | 6.78 | 22.95 |
| Net profit (TTM) | $8.41B | $21.60B |
| Revenue (TTM) | $30.46B | $79.67B |
| Revenue growth (YoY) | +10.2% | +47.7% |
| Gross margin | 79.6% | 83.4% |
| Operating margin | 38.5% | 49.7% |
| Net margin | -10.6% | 33.5% |
| Free cash flow (TTM) | $12.94B | $13.56B |
| Ownership & sentiment | ||
| Institutional ownership | 91.3% | 79.3% |
| Insider activity (12mo) | 18 buy / 32 sell | 37 buy / 13 sell |
| Short interest (% of float) | 1.8% | 0.7% |
| Analyst consensus | 89% buy / 11% hold (19) | 91% buy / 5% hold / 5% sell (22) |
| Analyst price target | $163 (+8%) | $1,383 (+17%) |
| StockVane view | ||
| StockVane Quant Rating | B (70) | B (77) |
| Company | ||
| Employees | 17,000 | 50,000 |
| Founded | 1987 | 1876 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.